Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...